First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid TumorsMichael L. Maitland, Emiliano Calvo, Shivaani Kummar et al.|Clinical Cancer Research|2021Cited by 81